Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 13, 2022 / 10:20PM GMT
Release Date Price: €30.52 (-10.05%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thank you, everyone, for joining us. We're really pleased to have Sage with us, and we have Barry Greene, CEO of the company. Barry, with that, I'm going to turn it over to you for any opening remarks, and then we can jump in.

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Yes. Well, thanks. It's great being and thanks for everyone in the audience for being here. Really quickly, we've got a couple updates. One that came out this morning where we articulated that we were able to accelerate the PPD aspect of the NDA and do 1 filing for both PPD and MDD. We're excited by that because it simplifies the review process. It's better for us, it's better for the agency to have 1 filing. So that was one of the updates this morning.

The second update, which we hadn't updated folks on is that the SHORELINE study is completing enrollment. We were able to roll a majority of the patients from CORAL on the SHORELINE and that allows us to wrap up

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot